Current and Emerging Approaches to Attain Remission in Ulcerative Colitis
Jointly sponsored by the University of Cincinnati and Princeton CME
Target Audience
This activity is designed for managed markets physicians and pharmacists.
Learning Objectives
After completing this activity, participants should be able to:
- Recognize the physical and psychological burden of ulcerative colitis in the United States
- Differentiate ulcerative colitis from similar inflammatory bowel diseases
- Describe the impact of adverse effects on ulcerative colitis treatment decisions
- Apply clinical and economic data to assess the role of different pharmacotherapeutic regimens in the management of ulcerative colitis from a managed markets perspective.
Credit Eligibility
To be eligible for documentation of credit, all participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit. Those who mail or fax back their successfully completed post-test and evaluation form will receive documentation of credit by mail within 6 weeks.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
Release date: August 15, 2007; Expiration date: October 10, 2008
Estimated time to complete: 1 hour
There is no fee associated with this activity.
CME Accreditation
This educational activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and Princeton CME. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CPE Accreditation
Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 hour credit (0.1 CEU) of continuing pharmacy education (ACPE #452-999-07-009-H01).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Continuing Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.
Grant Support
Supported by an educational grant from Shire Pharmaceuticals Inc.
Presenter
William J. Sandborn, MD
Professor of Medicine
Mayo Clinic College of Medicine
Vice Chairman
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota
Independent Clinical Reviewer
Mark Reichelderfer, MD
Professor of Medicine
Section of Gastroenterology and Hepatology
University of Wisconsin
Madison, Wisconsin
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of the University of Cincinnati and Princeton CME, faulty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Reichelderfer: Research support—Proctor & Gamble
Dr. Sandborn: Research—Abbott, Centocor, Proctor & Gamble, Shire Pharmaceuticals, UCB; Consultant—Abbott, Centocor, Proctor & Gamble, Salix Pharmaceuticals, Shire Pharmaceuticals, UCB
Planning Committee: Kay Weigand, University of Cincinnati; Randy Robbin and John Savage, Princeton CME; Mary Johnson, Princeton Media Associates have disclosed no relevant financial relationships with any commercial interests.
The University of Cincinnati and Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.
The following off-label/unapproved drugs or devices are discussed: treatment of ulcerative colitis with abciximab.
Some of the clinical studies discussed in this activity may have been funded by manufacturers of drugs or devices.
Editor’s Note: With approval from the University of Cincinnati, this continuing medical education activity includes medication brand names for participant clarity purposes only, due to like-named chemicals with varying delivery systems. No product promotion or recommendations should be inferred.
